NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ARGX

Argen X SE ADR

Jul 01 • 04:00PM ET

542.47

Dollar change -8.75
Percentage change -1.59	%

Healthcare • Biotechnology • Netherlands • NASD

Peers: REGN VRTX BIIB INCY IONS GILD NBIX RCUS FGEN XBIT

| Held by: IBB CGGO FBT BBH QQQJ DFAI AVDE ONEQ FDG TGRT

Scroll to Statements

Index	-	P/E	42.53	EPS (ttm)	12.76	Insider Own	0.35%	Shs Outstand	61.06M	Perf Week	-4.50%
Market Cap	33.12B	Forward P/E	25.72	EPS next Y	21.09	Insider Trans	0.00%	Shs Float	60.85M	Perf Month	-5.37%
Enterprise Value	29.78B	PEG	1.30	EPS next Q	2.98	Inst Own	54.72%	Short Float	3.32%	Perf Quarter	-8.35%
Income	831.41M	P/S	15.15	EPS this Y	0.90%	Inst Trans	-2.45%	Short Ratio	4.73	Perf Half Y	-14.17%
Sales	2.19B	P/B	5.99	EPS next Y	63.56%	ROA	15.48%	Short Interest	2.02M	Perf YTD	-11.79%
Book/sh	90.49	P/C	9.80	EPS next 5Y	32.73%	ROE	17.33%	52W High	678.21 -20.01%	Perf Year	21.92%
Cash/sh	55.34	P/FCF	1224.52	EPS past 3/5Y	- -	ROIC	15.03%	52W Low	428.97 26.46%	Perf 3Y	48.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	63.91% 94.72%	Gross Margin	89.20%	Volatility	3.64% 2.58%	Perf 5Y	142.39%
Dividend TTM	-	EV/Sales	13.62	EPS Y/Y TTM	368.72%	Oper. Margin	-3.46%	ATR (14)	17.32	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.68	Sales Y/Y TTM	78.01%	Profit Margin	38.03%	RSI (14)	39.77	Recom	1.30
Dividend Gr. 3/5Y	- -	Current Ratio	7.29	EPS Q/Q	-	SMA20	-3.74%	Beta	0.37	Target Price	755.73
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-6.61%	Rel Volume	1.42	Prev Close	551.22
Employees	1599	LT Debt/Eq	0.01	Earnings	May 08 BMO	SMA200	-8.69%	Avg Volume	427.14K	Price	542.47
IPO	May 18, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.57% 2.55%	Trades		Volume	606,590	Change	-1.59%

Date	Action	Analyst	Rating Change	Price Target Change
May-13-25	Upgrade	Robert W. Baird	Neutral → Outperform	$680
Mar-17-25	Upgrade	Bernstein	Mkt Perform → Outperform
Mar-12-25	Upgrade	Deutsche Bank	Sell → Hold
Jan-17-25	Downgrade	Deutsche Bank	Hold → Sell
Nov-12-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$697
Nov-05-24	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$715
Nov-01-24	Upgrade	William Blair	Mkt Perform → Outperform
Nov-01-24	Downgrade	Robert W. Baird	Outperform → Neutral	$515 → $650
Oct-10-24	Resumed	Raymond James	Strong Buy	$605
Oct-04-24	Downgrade	Deutsche Bank	Buy → Hold
Aug-06-24	Upgrade	Barclays	Equal Weight → Overweight
Jul-25-24	Upgrade	Deutsche Bank	Hold → Buy
Jul-23-24	Upgrade	Oppenheimer	Perform → Outperform	$546
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Dec-20-23	Downgrade	Deutsche Bank	Buy → Hold
Jul-31-23	Initiated	Scotiabank	Sector Perform	$516
Jul-24-23	Downgrade	UBS	Buy → Neutral	$480 → $570
Jul-17-23	Resumed	Evercore ISI	Outperform	$436
Jun-15-23	Initiated	Societe Generale	Sell

Show Previous Ratings

Jun-30-25 11:31AM	BofA Remains Bullish on Argenx (ARGX) With a Buy Rating and $804 PT (Insider Monkey)
01:00AM	argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes (GlobeNewswire)
Jun-24-25 12:45PM	Argenx Secures EC Approval for Subcutaneous VYVGART in CIDP Treatment (Insider Monkey) +5.05%
Jun-20-25 01:00PM	argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (GlobeNewswire)
Jun-17-25 11:40AM	EXEL or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
06:01PM	Loading…
Jun-10-25 06:01PM	argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease (GlobeNewswire)
Jun-06-25 04:30PM	argenx SE (ARGX): A Bull Case Theory (Insider Monkey)
04:00PM	This IBD 50 Biotech's Got 'Rhythm' And Flashes 3 Telltale Clues (Investor's Business Daily)
Jun-03-25 09:09AM	Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last? (Zacks)
01:00AM	argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-29-25 09:00AM	Argenx added to Best Ideas List at Wedbush (TipRanks)
May-28-25 04:01PM	argenx Announces Results of Annual General Meeting of Shareholders (GlobeNewswire)
May-23-25 11:40AM	EXEL vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
May-13-25 10:16PM	argenx SE (ARGX): Among the Best Growth Stocks to Buy and Hold for the Long Term (Insider Monkey)
May-12-25 12:00PM	Argenx (ARGX) Upgraded to Buy: Here's Why (Zacks)
08:30PM	Loading…
May-09-25 08:30PM	Analyst Report: argenx SE (Morningstar Research)
10:25AM	argenx SE (ARGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
03:18AM	argenx SE (ARGX) Q1 2025 Earnings Call Highlights: Record Growth and Strategic Advances (GuruFocus.com)
May-08-25 08:55AM	Argenx Beats Sales Expectations But Not By Enough And Shares Tumble (Investor's Business Daily) -8.64%
01:00AM	argenx Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:11PM	Argenx SE Q1 2025 Earnings Preview (Seeking Alpha)
11:02AM	argenx SE (ARGX): A Bull Case Theory (Insider Monkey)
04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-06-25 11:40AM	AZN or ARGX: Which Is the Better Value Stock Right Now? (Zacks) -6.33%
01:00AM	argenx to Present at BofA Securities 2025 Health Care Conference (GlobeNewswire)
May-05-25 12:12PM	ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? (Zacks)
09:54AM	Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock? (Zacks)
07:12AM	Novavax to Report First-Quarter Earnings: Is a Beat in Store? (Zacks)
May-02-25 01:23PM	BioMarin's First-Quarter Earnings & Sales Beat Estimates (Zacks)
03:33AM	Loading…
May-01-25 03:33AM	Is argenx SE (ARGX) the Most Profitable Growth Stock to Buy Now? (Insider Monkey)
01:00AM	argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 (GlobeNewswire)
Apr-30-25 10:55PM	ClearBridge International Growth Fund Q1 2025 Commentary (Seeking Alpha)
01:06PM	Argenx Stock Extends Rally In A Base As Earnings Loom (Investor's Business Daily)
09:40AM	Is Roche Holding (RHHBY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-29-25 11:59AM	Corcept Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
07:51AM	Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards? (Zacks)
Apr-28-25 09:14AM	GSK to Report First-Quarter Earnings: Is a Beat in Store? (Zacks)
09:04AM	Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect (Zacks)
01:00AM	argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (GlobeNewswire)
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-25-25 01:29PM	Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? (Zacks)
11:57AM	Can Moderna Keep the Beat Streak Alive This Earnings Season? (Zacks)
11:16AM	Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? (Zacks)
10:14AM	CytomX Gears Up to Report Q1 Earnings: Here's What to Expect (Zacks)
09:25AM	Beam Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-24-25 10:15AM	Artisan International Fund Q1 2025 Commentary (Seeking Alpha)
09:55AM	Wall Street Analysts Believe Argenx (ARGX) Could Rally 25.8%: Here's is How to Trade (Zacks)
Apr-23-25 09:25AM	Amicus Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
07:50AM	Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know (Zacks)
Apr-22-25 10:39AM	Verastem Oncology to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-21-25 07:36AM	Viking Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-17-25 11:40AM	JAZZ vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
Apr-15-25 08:09AM	Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last? (Zacks)
Apr-14-25 02:03PM	Is Argenx SE (ARGX) the Best Growth Stock to Buy According to Billionaires? (Insider Monkey)
Apr-11-25 05:41PM	FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting (Benzinga) +6.36%
04:01PM	argenx Announces Annual General Meeting of Shareholders on May 27, 2025 (GlobeNewswire)
10:15AM	Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug (Investor's Business Daily)
Apr-10-25 05:47PM	argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy (GlobeNewswire)
01:26PM	argenx SE (ARGX): Among the Aggressive Stocks Picked by Hedge Funds (Insider Monkey)
Apr-09-25 06:33AM	ClearBridge International Growth EAFE Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-08-25 02:17PM	Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients (Benzinga)
01:00AM	argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP (GlobeNewswire)
Apr-04-25 02:30PM	Stock Picks From Seeking Alpha's March 2025 New Analysts (Seeking Alpha) -5.92%
Apr-02-25 09:47AM	Is Argenx SE (ARGX) The Most Profitable Biotech Stock To Buy Right Now? (Insider Monkey)
Mar-31-25 11:40AM	JAZZ or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Mar-27-25 07:30AM	Franklin Biotechnology Discovery Fund Q4 2024 Commentary (SeekingAlpha)
Mar-24-25 01:56PM	Argenx: The Magic May Be Already Priced In (SeekingAlpha)
Mar-19-25 05:07PM	Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (SeekingAlpha)
Mar-17-25 09:35AM	Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains? (Zacks)
Mar-11-25 08:17AM	Artisan Small Cap Fund Sold argenx SE (ARGX) as it Exceeded Small-Cap Mandate (Insider Monkey)
Mar-07-25 01:00AM	argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire)
Mar-04-25 04:50PM	Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity (Investor's Business Daily)
Feb-28-25 09:24PM	Analyst Report: argenx SE (Morningstar Research)
Feb-27-25 01:00AM	argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
Feb-25-25 01:00AM	argenx to Present at TD Cowen 45th Annual Healthcare Conference (GlobeNewswire)
Feb-21-25 04:58PM	These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50 (Investor's Business Daily)
Feb-20-25 01:00AM	argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 (GlobeNewswire)
Feb-19-25 10:58AM	Heres Why argenx SE (ARGX) Rose in Q4 (Insider Monkey)
07:10AM	Q4 2024 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Jan-30-25 09:40AM	Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-23-25 02:19AM	Is argenx SE (ARGX) the High Growth International Stock to Invest in Now? (Insider Monkey)
02:17AM	Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now? (Insider Monkey)
Jan-17-25 12:20PM	Earnings Estimates Rising for Argenx (ARGX): Will It Gain? (Zacks)
Jan-13-25 01:00AM	argenx Highlights 2025 Strategic Priorities (GlobeNewswire)
Jan-06-25 01:00AM	argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-28-24 06:28AM	Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment (TipRanks)
Dec-27-24 01:00AM	argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (GlobeNewswire)
Dec-23-24 10:28AM	Is Argenx SE (ARGX) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-12-24 09:30AM	Heres Why argenx SE (ARGX) Surged in Q3 (Insider Monkey)
Dec-09-24 09:10AM	Should You Increase Your Holdings in argenx SE (ARGX)? (Insider Monkey)
Dec-02-24 02:55PM	Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now? (Insider Monkey)
Nov-26-24 01:00AM	argenx to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-22-24 05:30AM	Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial (BioPharma Dive)
Nov-20-24 01:00AM	argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies (GlobeNewswire)
Nov-18-24 09:10AM	Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now? (Insider Monkey)
Nov-11-24 07:30AM	Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China (Business Wire)
07:30AM	argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China (GlobeNewswire)
Nov-05-24 12:20PM	Why Argenx (ARGX) Might be Well Poised for a Surge (Zacks)
01:00AM	argenx to Participate at Upcoming Investor Conferences (GlobeNewswire)

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARGX

Argen X SE ADR

Upgrade your FINVIZ experience